Biotech first quarter revenue: Bora, the stock king, declines by 40%, while PEGAVISION, the stock runner-up, achieves historic high for the same period

The first-quarter revenue of biotech stocks has been released. Bora, the stock king, saw a 40% decrease in revenue due to no longer representing low-margin cancer drugs. In contrast, PEGAVISION, the stock runner-up, has set a new high for the same period in history, with an 18.2% increase in revenue. Contact lens companies generally performed well, with Xuan Yu in the beauty and health group increasing by 58.23% annually, and Grape King reaching a historic high for the same period with a 5.76% increase.